Efficacy and safety of adalimumab in Chinese patients with moderately to severely active Crohn’s disease: results from a randomized trial

BACKGROUND AND AIMS: Efficacy of adalimumab in Crohn’s disease (CD) has not been shown in China. The aim of this study was to evaluate the efficacy and safety of adalimumab in Chinese patients with CD. METHODS: This 26-week, multicenter, phase III study evaluated patients with moderately to severely...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Baili, Gao, Xiang, Zhong, Jie, Ren, Jianlin, Zhu, Xuan, Liu, Zhanju, Wu, Kaichun, Kalabic, Jasmina, Yu, Zhuqing, Huang, Bidan, Kwatra, Nisha, Doan, Thao, Robinson, Anne M., Chen, Min-Hu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7370564/
https://www.ncbi.nlm.nih.gov/pubmed/32733600
http://dx.doi.org/10.1177/1756284820938960

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7370564/
https://www.ncbi.nlm.nih.gov/pubmed/32733600
http://dx.doi.org/10.1177/1756284820938960

Ejemplares similares